KLB and metabolic dysfunction-associated steatohepatitis: NAFLDsym has additionally been used to simulate several potential treatments for NASH patients (e.g., anti-FGFR1/KLB bispecific antibody, cenicriviroc), including those that elicited improvements in NASH and others that did not (36, 37).